| Antibiotic adjuvants–A strategy to unlock bacterial resistance to antibiotics C González-Bello Bioorganic & medicinal chemistry letters 27 (18), 4221-4228, 2017 | 275 | 2017 |
| β-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs C González-Bello, D Rodríguez, M Pernas, Á Rodríguez, E Colchón Journal of medicinal chemistry 63 (5), 1859-1881, 2019 | 158 | 2019 |
| Designing irreversible inhibitors—worth the effort? C González‐Bello ChemMedChem 11 (1), 22-30, 2016 | 88 | 2016 |
| Evidence from kinetic isotope studies for an enolate intermediate in the mechanism of type II dehydroquinases JM Harris, C Gonzalez-Bello, C Kleanthous, AR Hawkins, JR Coggins, ... Biochemical journal 319 (Pt 2), 333, 1996 | 86 | 1996 |
| Mycobacterium tuberculosis shikimate kinase inhibitors: design and simulation studies of the catalytic turnover B Blanco, V Prado, E Lence, JM Otero, C Garcia-Doval, MJ van Raaij, ... Journal of the American Chemical Society 135 (33), 12366-12376, 2013 | 84 | 2013 |
| Using surface enhanced Raman scattering to analyze the interactions of protein receptors with bacterial quorum sensing modulators C Costas, V López-Puente, G Bodelón, C Gonzalez-Bello, J Perez-Juste, ... ACS nano 9 (5), 5567-5576, 2015 | 61 | 2015 |
| Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas … J Arca-Suárez, C Lasarte-Monterrubio, BK Rodiño-Janeiro, G Cabot, ... Journal of Antimicrobial Chemotherapy 76 (1), 91-100, 2021 | 52 | 2021 |
| Structure-Based Design, Synthesis, and Biological Evaluation of Inhibitors of Mycobacterium tuberculosis Type II Dehydroquinase C Sánchez-Sixto, VFV Prazeres, L Castedo, H Lamb, AR Hawkins, ... Journal of medicinal chemistry 48 (15), 4871-4881, 2005 | 49 | 2005 |
| Selection of AmpC β-lactamase variants and metallo-β-lactamases leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance during treatment of MDR/XDR Pseudomonas … A Ruedas-López, I Alonso-García, C Lasarte-Monterrubio, ... Antimicrobial Agents and Chemotherapy 66 (2), e02067-21, 2022 | 45 | 2022 |
| A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors L Tizon, JM Otero, VFV Prazeres, AL Llamas-Saiz, GC Fox, MJ van Raaij, ... Journal of medicinal chemistry 54 (17), 6063-6084, 2011 | 43 | 2011 |
| LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48 JA Vallejo, M Martinez-Guitian, JC Vázquez-Ucha, C González-Bello, ... Journal of Antimicrobial Chemotherapy 71 (8), 2171-2180, 2016 | 40 | 2016 |
| Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection J Arca-Suárez, JC Vázquez-Ucha, PA Fraile-Ribot, E Lence, G Cabot, ... Journal of Antimicrobial Chemotherapy 75 (11), 3209-3217, 2020 | 38 | 2020 |
| Progress in type II dehydroquinase inhibitors: from concept to practice C González‐Bello, L Castedo Medicinal Research Reviews 27 (2), 177-208, 2007 | 38 | 2007 |
| Synthesis of (2R)-2-bromodehydroquinic acid and (2R)-2-fluorodehydroquinic acid MK Manthey, C González-Bello, C Abell Journal of the Chemical Society, Perkin Transactions 1, 625-628, 1997 | 38 | 1997 |
| Activity of the β-lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii JC Vázquez-Ucha, M Maneiro, M Martínez-Guitián, J Buynak, CR Bethel, ... Antimicrobial Agents and Chemotherapy 61 (11), 10.1128/aac. 01172-17, 2017 | 37 | 2017 |
| Inhibition of shikimate kinase and type II dehydroquinase for antibiotic discovery: structure-based design and simulation studies C Gonzalez-Bello Current Topics in Medicinal Chemistry 16 (9), 960-977, 2016 | 31 | 2016 |
| Understanding the Key Factors that Control the Inhibition of Type II Dehydroquinase by (2R)‐2‐Benzyl‐3‐dehydroquinic Acids A Peón, JM Otero, L Tizón, VFV Prazeres, AL Llamas‐Saiz, GC Fox, ... ChemMedChem 5 (10), 1726-1733, 2010 | 30 | 2010 |
| Nanomolar Competitive Inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor Type II Dehydroquinase VFV Prazeres, C Sánchez‐Sixto, L Castedo, H Lamb, AR Hawkins, ... ChemMedChem: Chemistry Enabling Drug Discovery 2 (2), 194-207, 2007 | 30 | 2007 |
| Synthesis of 3-alkyl enol mimics inhibitors of type II dehydroquinase: factors influencing their inhibition potency A Peón, L Castedo, C González-Bello, B Blanco, H Lamb, A Sedes, ... Organic Biomolecular Chemistry, 2012 | 29 | 2012 |
| Challenging antimicrobial susceptibility and evolution of resistance (OXA-681) during treatment of a long-term nosocomial infection caused by a Pseudomonas aeruginosa ST175 clone J Arca-Suárez, P Fraile-Ribot, JC Vázquez-Ucha, G Cabot, ... Antimicrobial agents and chemotherapy 63 (10), 10.1128/aac. 01110-19, 2019 | 28 | 2019 |
Juan C Vázquez-Ucha (ORCID 0000-...Researcher. Complexo Hospitalario Universitario A Coruña (CHUAC)- INIBICVerified email at sergas.es
